# US 2012/0252776 A1 · C4 Monomethyl Triterpenoid Derivatives and Methods of Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252776 A1
- Document ID: US20120252776A1
- Status: Published application
- Kind: A1
- Application number: 13/417,519
- Filed: 2012-03-12
- Published: 2012-10-04
- Earliest claimed: 2011-03-11
- Assignees: Reata Pharmaceuticals, Inc.
- Inventors: Eric Anderson; Christopher F. Bender; Xiaofeng Liu; Xin Jiang; Melean Visnick
- Web page: https://patentgrep.com/patent/US20120252776A1

## CPC

- C07J 63/008: {Expansion of ring D by one atom, e.g. D homo steroids}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/06: Antipsoriatics
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 39/06: Free radical scavengers or antioxidants
- C07J 71/0005: {Oxygen-containing hetero ring}
- C07J: STEROIDS (seco-steroids C07C)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are novel C4-monomethyl triterpenoid compounds and derivatives thereof, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example as antioxidant inflammation modulators, and compositions thereof are also provided.

## Claims

### Claim 1

A compound of the formula:
wherein:
X1 and X2 are independently hydrogen, halo, hydroxy, amino or oxo, provided that X1 is not oxo when carbon atoms 12 and 13 are connected to one another with a double bond, further provided that X2 is not oxo when carbon atoms 9 and 11 are connected to one another with a double bond;
R1 is —H, —CN, halo, —CF3, or —C(O)Ra, wherein Ra is —OH, alkoxy(C1-4), NH2, alkylamino(C1-4), or —NH—S(O)2-alkyl(C1-4);
R2 is hydrogen or R2 is absent when the atom to which it is bound forms part of a double bond;
R2′ is hydrogen, ═CH2, alkyl(C≦8), or substituted alkyl(C≦8),
R3 and R4 are each independently hydrogen, hydroxy, methyl or as defined below when either of these groups is taken together with group Rc; and
Y is:
—H, —OH, —SH, —CN, —F, —CF3, —NH2 or —NCO;
alkyl(C≦8), alkenyl(C≦8), alkynyl(C≦8), aryl(C≦12), aralkyl(C≦12), heteroaryl(C≦8), heterocycloalkyl(C≦12), alkoxy(C≦8), aryloxy(C≦12), acyloxy(C≦8), alkylamino(C≦8), dialkylamino(C≦8), alkenylamino(C≦8), arylamino(C≦8), aralkylamino(C≦8), alkylthio(C≦8), acylthio(C≦8), alkylsulfonylamino(C≦8), or substituted versions of any of these groups;
-alkanediyl(C≦8)-Rb, -alkenediyl(C≦8)-Rb, or a substituted version of any of these groups, wherein Rb is:
hydrogen, hydroxy, halo, amino or thio; or
heteroaryl(C≦8), alkoxy(C≦8), alkenyloxy(C≦8), aryloxy(C≦8), aralkoxy(C≦8), heteroaryloxy(C≦8), acyloxy(C≦8), alkylamino(C≦8), dialkylamino(C≦8), alkenylamino(C≦8), arylamino(C≦8), aralkylamino(C≦8), heteroarylamino(C≦8), alkylsulfonylamino(C≦8), amido(C≦8), —OC(O)NH-alkyl(C≦8), —OC(O)CH2NHC(O)O-t-butyl, —OCH2-alkylthio(C≦8), or a substituted version of any of these groups;
—(CH2)m(O)Rc, wherein m is 0-6 and Rc is:
hydrogen, hydroxy, halo, amino, —NHOH,
or thio; or
alkyl(C≦8), alkenyl(C≦8), alkynyl(C≦8), aryl(C≦8), aralkyl(C≦8), heteroaryl(C≦8), heterocycloalkyl(C≦8), alkoxy(C≦8), alkenyloxy(C≦8), aryloxy(C≦8), aralkoxy(C≦8), heteroaryloxy(C≦8), acyloxy(C≦8), alkylamino(C≦8), dialkylamino(C≦8), arylamino(C≦8), alkylsulfonylamino(C≦8), amido(C≦8), —NH-alkoxy(C≦8), —NH-heterocycloalkyl(C≦8), —NHC(NOH)-alkyl(C≦8), —NH-amido(C≦8), or a substituted version of any of these groups;
R1 and R3, taken together, are —O— or —NRd—, wherein Rd is hydrogen or alkyl(C≦4); or
Rc and R4, taken together, are —O— or —NRd—, wherein Rd is hydrogen or alkyl(C≦4); or
—NHC(O)Re, wherein Re is:
hydrogen, hydroxy, amino; or
alkyl(C≦8), alkenyl(C≦8), alkynyl(C≦8), aryl(C≦8), aralkyl(C≦8), heteroaryl(C≦8), heterocycloalkyl(C≦8), alkoxy(C≦8), aryloxy(C≦8), aralkoxy(C≦8), heteroaryloxy(C≦8), acyloxy(C≦8), alkylamino(C≦8), dialkylamino(C≦8), arylamino(C≦8), or a substituted version of any of these groups;
or a pharmaceutically acceptable salt or tautomer thereof.

### Claim 2 (depends on 1)

The compound of claim 1, further defined by the formula:
wherein:
R1 is —H, —CN, halo, —CF3, or —C(O)Ra, wherein Ra is —OH, alkoxy(C1-4), —NH2, alkylamino(C1-4), or —NH—S(O)2-alkyl(C1-4),
R2 is hydrogen or R2 is absent when the atom to which it is bound forms part of a double bond; and
Y is:
—H, —OH, —CN, —F, —CF3, —NH2 or —NCO;
alkyl(C≦8), alkenyl(C≦8), alkynyl(C≦8), aryl(C≦12), aralkyl(C≦12), heteroaryl(C≦8), heterocycloalkyl(C≦12), alkoxy(C≦8), aryloxy(C≦12), acyloxy(C≦8), alkylamino(C≦8), dialkylamino(C≦8), alkenylamino(C≦8), arylamino(C≦8), aralkylamino(C≦8), alkylthio(C≦8), acylthio(C≦8), alkylsulfonylamino(C≦8), or substituted versions of any of these groups;
-alkanediyl(C≦8)-Rb, -alkenediyl(C≦8)-Rb, or a substituted version of any of these groups, wherein Rb is:
hydrogen, hydroxy, halo, amino or thio; or
heteroaryl(C≦8), alkoxy(C≦8), alkenyloxy(C≦8), aryloxy(C≦8), aralkoxy(C≦8), heteroaryloxy(C≦8), acyloxy(C≦8), alkylamino(C≦8), dialkylamino(C≦8), alkenylamino(C≦8), arylamino(C≦8), aralkylamino(C≦8), heteroarylamino(C≦8), alkylsulfonylamino(C≦8), amido(C≦8), —OC(O)NH-alkyl(C≦8), —OC(O)CH2NHC(O)O-t-butyl, —OCH2-alkylthio(C≦8), or a substituted version of any of these groups;
—(CH2)m(O)Rc, wherein m is 0-6 and Rc is:
hydrogen, hydroxy, halo, amino, —NHOH,
or thio; or
alkyl(C≦8), alkenyl(C≦8), alkynyl(C≦8), aryl(C≦8), aralkyl(C≦8), heteroaryl(C≦8), heterocycloalkyl(C≦8), alkoxy(C≦8), alkenyloxy(C≦8), aryloxy(C≦8), aralkoxy(C≦8), heteroaryloxy(C≦8), acyloxy(C≦8), alkylamino(C≦8), dialkylamino(C≦8), arylamino(C≦8), alkylsulfonylamino(C≦8), amido(C≦8), —NH-alkoxy(C≦8), —NH-heterocycloalkyl(C≦8), —NHC(NOH)-alkyl(C≦8), —NH-amido(C≦8), or a substituted version of any of these groups; or
—NHC(O)Re, wherein Re is:
hydrogen, hydroxy, amino; or
alkyl(C≦8), alkenyl(C≦8), alkynyl(C≦8), aryl(C≦8), aralkyl(C≦8), heteroaryl(C≦8), heterocycloalkyl(C≦8), alkoxy(C≦8), aryloxy(C≦8), aralkoxy(C≦8), heteroaryloxy(C≦8), acyloxy(C≦8), alkylamino(C≦8), dialkylamino(C≦8), arylamino(C≦8), or a substituted version of any of these groups;
or a pharmaceutically acceptable salt or tautomer thereof.

### Claim 3 (depends on 2)

The compound of claim 2, further defined by the formula:
wherein:
R1 is —H, —CN, halo, —CF3, or —C(O)Ra, wherein Ra is —OH, alkoxy(C1-4), —NH2, alkylamino(C1-4), or —NH—S(O)2-alkyl(C1-4); and
Y is:
—H, —OH, —SH, —F, —CF3, —NH2 or —NCO;
alkyl(C≦8), alkenyl(C≦8), alkynyl(C≦8), aryl(C≦12), aralkyl(C≦12), heteroaryl(C≦8), heterocycloalkyl(C≦12), alkoxy(C≦8), aryloxy(C≦12), acyloxy(C≦8), alkylamino(C≦8), dialkylamino(C≦8), alkenylamino(C≦8), arylamino(C≦8), aralkylamino(C≦8), alkylthio(C≦8), acylthio(C≦8), alkylsulfonylamino(C≦8), or substituted versions of any of these groups;
-alkanediyl(C≦8)-Rb, -alkenediyl(C≦8)-Rb, or a substituted version of any of these groups, wherein Rb is:
hydrogen, hydroxy, halo, amino or thio; or
heteroaryl(C≦8), alkoxy(C≦8), alkenyloxy(C≦8), aryloxy(C≦8), aralkoxy(C≦8), heteroaryloxy(C≦8), acyloxy(C≦8), alkylamino(C≦8), dialkylamino(C≦8), alkenylamino(C≦8), arylamino(C≦8), aralkylamino(C≦8), heteroarylamino(C≦8), alkylsulfonylamino(C≦8), amido(C≦8), —OC(O)NH-alkyl(C≦8), —OC(O)CH2NHC(O)O-t-butyl, —OCH2-alkylthio(C≦8), or a substituted version of any of these groups;
—(CH2)mC(O)Rc, wherein m is 0-6 and Rc is:
hydrogen, hydroxy, halo, amino, —NHOH,
or thio; or
alkyl(C≦8), alkenyl(C≦8), alkynyl(C≦8), aryl(C≦8), aralkyl(C≦8), heteroaryl(C≦8), heterocycloalkyl(C≦8), alkoxy(C≦8), alkenyloxy(C≦8), aryloxy(C≦8), aralkoxy(C≦8), heteroaryloxy(C≦8), acyloxy(C≦8), alkylamino(C≦8), dialkylamino(C≦8), arylamino(C≦8), alkylsulfonylamino(C≦8), amido(C≦8), —NH-alkoxy(C≦8), —NH-heterocycloalkyl(C≦8), —NHC(NOH)-alkyl(C≦8), —NH-amido(C≦8), or a substituted version of any of these groups; or
—NHC(O)Re, wherein Re is:
hydrogen, hydroxy, amino; or
alkyl(C≦8), alkenyl(C≦8), alkynyl(C≦8), aryl(C≦8), aralkyl(C≦8), heteroaryl(C≦8), heterocycloalkyl(C≦8), alkoxy(C≦8), aryloxy(C≦8), aralkoxy(C≦8), heteroaryloxy(C≦8), acyloxy(C≦8), alkylamino(C≦8), dialkylamino(C≦8), arylamino(C≦8), or a substituted version of any of these groups;
or a pharmaceutically acceptable salt or tautomer thereof.

### Claim 4 (depends on 3)

The compound of claim 3, further defined by the formula:
wherein:
R1 is —H, —CN, halo, —CF3, or —C(O)Ra, wherein Ra is —OH, alkoxy(C1-4), —NH2, alkylamino(C1-4), or —NH—S(O)2-alkyl(C1-4); and
Y is:
—H, —OH, —SH, —CN, —F, —CF3, —NH2 or —NCO;
alkyl(C≦8), alkenyl(C≦8), alkynyl(C≦8), aryl(C≦12), aralkyl(C≦12), heteroaryl(C≦8), heterocycloalkyl(C≦12), alkoxy(C≦8), aryloxy(C≦12), acyloxy(C≦8), alkylamino(C≦8), dialkylamino(C≦8), alkenylamino(C≦8), arylamino(C≦8), aralkylamino(C≦8), amido(C≦8), alkylthio(C≦8), acylthio(C≦8), alkylsulfonylamino(C≦8), or substituted versions of any of these groups;
-alkanediyl(C≦8)-Rb, -alkenediyl(C≦8)-Rb, or a substituted version of any of these groups, wherein Rb is:
hydrogen, hydroxy, halo, amino or thio; or
heteroaryl(C≦8), alkoxy(C≦8), alkenyloxy(C≦8), aryloxy(C≦8), aralkoxy(C≦8), heteroaryloxy(C≦8), acyloxy(C≦8), alkylamino(C≦8), dialkylamino(C≦8), alkenylamino(C≦8), arylamino(C≦8), aralkylamino(C≦8), heteroarylamino(C≦8), alkylsulfonylamino(C≦8), amido(C≦8), —OC(O)NH-alkyl(C≦8), OC(O)CH2NHC(O)O-t-butyl, —OCH2-alkylthio(C≦8), or a substituted version of any of these groups;
—(CH2)mC(O)Rc, wherein m is 0-6 and Rc is:
hydrogen, hydroxy, halo, amino, —NHOH,
or thio; or
alkyl(C≦8), alkenyl(C≦8), alkynyl(C≦8), aryl(C≦8), aralkyl(C≦8), heteroaryl(C≦8), heterocycloalkyl(C≦8), alkoxy(C≦8), alkenyloxy(C≦8), aryloxy(C≦8), aralkoxy(C≦8), heteroaryloxy(C≦8), acyloxy(C≦8), alkylamino(C≦8), dialkylamino(C≦8), arylamino(C≦8), alkylsulfonylamino(C≦8), amido(C≦8), —NH-alkoxy(C≦8), —NH-heterocycloalkyl(C≦8), —NHC(NOH)-alkyl(C≦8), —NH-amido(C≦8), or a substituted version of any of these groups; or
—NHC(O)Re, wherein Re is:
hydrogen, hydroxy, amino; or
alkyl(C≦8), alkenyl(C≦8), alkynyl(C≦8), aryl(C≦8), aralkyl(C≦8), heteroaryl(C≦8), heterocycloalkyl(C≦8), alkoxy(C≦8), aryloxy(C≦8), aralkoxy(C≦8), heteroaryloxy(C≦8), acyloxy(C≦8), alkylamino(C≦8), dialkylamino(C≦8), arylamino(C≦8), or a substituted version of any of these groups;
or a pharmaceutically acceptable salt or tautomer thereof.

### Claim at position 5

5-15. (canceled)

### Claim 16 (depends on 4)

The compound of claim 4, wherein R1 is —CN.

### Claim at position 7

17-34. (canceled)

### Claim 35 (depends on 16)

The compound of claim 16, wherein Y is —(CH2)mC(O)Rc, wherein m is 0-6 and Rc is hydrogen, hydroxy, amino, —NHOH,
alkyl(C≦8), alkenyl(C≦8), alkynyl(C≦8), aryl(C≦8), aralkyl(C≦8), heteroaryl(C≦8), heterocycloalkyl(C≦8), alkoxy(C≦8), alkenyloxy(C≦8), aryloxy(C≦8), aralkoxy(C≦8), acyloxy(C≦8), alkylamino(C≦8), dialkylamino(C≦8), arylamino(C≦8), alkylsulfonylamino(C≦8), amido(C≦8), —NH-alkoxy(C≦8), —NH-heterocycloalkyl(C≦8), —NHC(NOH)-alkyl(C≦8), —NH-amido(C≦8), or a substituted version of any of these groups other than hydrogen, hydroxy, amino, and —NHOH.

### Claim 36 (depends on 35)

The compound of claim 35, wherein Rc is alkoxy(C≦8).

### Claim at position 10

37-39. (canceled)

### Claim 40 (depends on 35)

The compound of claim 35, wherein Rc is alkylamino(C≦8) or substituted alkylamino(C≦8).

### Claim 41

(canceled)

### Claim 42 (depends on 35)

The compound of claim 35, wherein Rc is heteroaryl(C≦8).

### Claim at position 14

43-44. (canceled)

### Claim 45 (depends on 35)

The compound of claim 35, wherein Rc is heterocycloalkyl(C≦8) or substituted heterocycloalkyl(C≦8).

### Claim 46

(canceled)

### Claim 47 (depends on 35)

The compound of claim 35, wherein Rc is —NH-heterocycloalkyl(C≦8).

### Claim at position 18

48-50. (canceled)

### Claim 51 (depends on 35)

The compound of claim 35, wherein m is 0.

### Claim 52

(canceled)

### Claim 53 (depends on 16)

The compound of claim 16, wherein Y is -alkanediyl(C≦8)-Rb.

### Claim 54 (depends on 53)

The compound of claim 53, wherein Y is —CH2—Rb.

### Claim 55

(canceled)

### Claim 56 (depends on 53)

The compound of claim 53, wherein Rb is acyloxy(C≦8) or substituted acyloxy(C≦8).

### Claim 57

(canceled)

### Claim 58 (depends on 53)

The compound of claim 53, wherein Rb is alkoxy(C≦8) or substituted alkoxy(C≦8).

### Claim 59

(canceled)

### Claim 60 (depends on 53)

The compound of claim 53, wherein Rb is heteroaryl(C≦8).

### Claim at position 29

61-64. (canceled)

### Claim 65 (depends on 16)

The compound of claim 16, wherein Y is alkylsulfonylamino(C≦8) or substituted alkylsulfonylamino(C≦8).

### Claim 66

(canceled)

### Claim 67 (depends on 16)

The compound of claim 16, wherein Y is heteroaryl(C≦8).

### Claim 68

(canceled)

### Claim 69 (depends on 16)

The compound of claim 16, wherein Y is —NHC(O)Re, wherein Re is hydrogen, hydroxy, amino, alkyl(C≦8), aryl(C≦8), alkoxy(C≦8), acyloxy(C≦8), alkylamino(C≦8), dialkylamino(C≦8), or substituted version of any of these groups other than hydrogen, hydroxy and amino.

### Claim at position 35

70-71. (canceled)

### Claim 72 (depends on 69)

The compound of claim 69, wherein Re is alkyl(C≦8) or substituted alkyl(C≦8).

### Claim 73

(canceled)

### Claim 74 (depends on 69)

The compound of claim 69, wherein Re is aryl(C≦8).

### Claim 75

(canceled)

### Claim 76 (depends on 69)

The compound of claim 69, wherein Re is alkoxy(C≦8).

### Claim 77

(canceled)

### Claim 78 (depends on 69)

The compound of claim 69, wherein Re is alkylamino(C≦8) or dialkylamino(C≦8).

### Claim at position 43

79-81. (canceled)

### Claim 82 (depends on 1)

The compound of claim 1, further defined as:
or a pharmaceutically acceptable salt or tautomer thereof.

### Claim 83 (depends on 1)

A pharmaceutical composition comprising:
a) the compound of claim 1; and
b) an excipient.

### Claim 84 (depends on 1)

A method of treating and/or preventing a disease or a disorder in a patient in need thereof, comprising administering to the patient a compound of claim 1 in an amount sufficient to treat and/or prevent the disease or disorder.
